Drug Profile
Sparsentan - Travere Therapeutics
Alternative Names: DARA; FILSPARI; PS-433540; RE-021Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Retrophin; Travere Therapeutics
- Class Anti-inflammatories; Antihypertensives; Isoxazoles; Nerve growth factors; Small molecules; Spiro compounds; Sulfonamides; Urologics; Vascular disorder therapies
- Mechanism of Action Angiotensin type 1 receptor antagonists; Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed IgA nephropathy
- Phase III Focal segmental glomerulosclerosis
- Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Hereditary nephritis; Vasculitis
- Discontinued Hypertension
Most Recent Events
- 13 Mar 2024 Travere Therapeutics expects to receive notice for sNDA acceptance for review from the FDA for sparsentan in IgA nephropathy in second quarter of 2024
- 11 Mar 2024 Travera Therapeutics submits sNDA for conversion of existing accelerated approval to full approval to US FDA for IgA nephropathy
- 27 Feb 2024 Travere therapeutics and CSL Vifor expects a European Commission decision for approval of conditional marketing authorisation for IgA nephropathy by Q2 2024